Results 61 to 70 of about 6,214,949 (261)
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages.
Chun Li +17 more
wiley +1 more source
Parkinson Disease Subtype Stability and Eventual Convergence
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Previous research identified distinct Parkinson disease (PD) clinical subtypes of “Motor Only,” “Psychiatric & Motor,” and “Cognitive & Motor” based on comprehensive, multidomain classification. Whether these subtypes reflect distinct trajectories or progressive disease stages remains unknown.
Laura M. Rosok +10 more
wiley +1 more source
Indian Journal of Psychological MedicineBackground: Inflammatory cytokines are associated with the pathophysiology of major depressive disorder (MDD). Nevertheless, whether they are trait or state biomarkers remains unclear.
Christopher Rockson +3 more
doaj +1 more source
Stress-evoked opioid release inhibits pain in major depressive disorder [PDF]
, 2008 To determine whether stress-evoked release of endogenous opioids might account for hypoalgesia in major depressive disorder (MDD), the μ-opioid antagonist naltrexone (50 mg) or placebo was administered double-blind to 24 participants with MDD and to 31 ...
Frew, A.K., Drummond, P.D.
core
Arthritis Care &Research, EarlyView.Biomedical research involving US veterans continues to advance health care beyond the Veterans Health Administration. This is particularly true in rheumatoid arthritis (RA), where veteran‐centric research has uncovered novel insights into pathogenesis, risk factors, and disease manifestations, informing clinical care and research across both veteran ...
Austin M. Wheeler +20 more
wiley +1 more source
Journal of International Medical ResearchObjective This study aimed to investigate the associations between serum nonenzymatic antioxidants and major depressive disorder or bipolar disorder in adolescents. Methods Cross-sectional (410 adolescents: 178 patients with major depressive disorder, 54
Zhenhong Jiang +14 more
doaj +1 more source
Affective bias and current, past and future adolescent depression: A familial high risk study. [PDF]
, 2015 Affective bias is a common feature of depressive disorder. However, a lack of longitudinal studies means that the temporal relationship between affective bias and depression is not well understood.
Collishaw, Stephan +11 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective To assess the validity of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric measures in patients with chronic nonbacterial osteomyelitis (CNO). Methods Within the longitudinal patient registry of CNO, English‐speaking patients aged 8 years and older self‐reported PROMIS Pediatric measures of fatigue, pain ...
Mary M. Eckert +43 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective The objective of this scoping review was to synthesize evidence on the proportion of individuals living with Sjögren's disease who experience central nervous system (CNS) manifestations. Methods We searched MEDLINE (via PubMed) and Embase from 1980 through January 29, 2026, and the ECRI Guidelines Trust from 2020 through January 29, 2026 ...
Arun Varadhachary +21 more
wiley +1 more source